Company: DARE
Filing Date: 2025-04-24
Form Type: DEF 14A
Source: 0001401914-25-000014
Chunk: 44

Company: Dare Bioscience, Inc.
Filing Date: 2025-04-24
Form: DEF 14A
Chunk 44
---
 of Directors                         |     |                 |        |
| Chair                                      |     |                 | 69,000 |
| Member                                     |     |                 | 39,000 |
| Board Committees                           |     |                 |        |
| Audit Chair                                |     |                 | 15,000 |
| Audit Member                               |     |                 |  7,500 |
| Compensation Chair                         |     |                 | 10,000 |
| Compensation Member                        |     |                 |  5,000 |
| Nominating and Corporate Governance Chair  |     |                 |  8,000 |
| Nominating and Corporate Governance Member |     |                 |  4,000 |

Equity Awards .

Annual Award . On the date of each annual meeting of stockholders, each director who has served on our Board for at least six months (and, if up for election at such annual meeting, is elected at such annual meeting) receives an option to purchase shares of our common stock, which will vest in full on the earlier of the first anniversary of the grant date or immediately prior to our first annual meeting of stockholders occurring after the grant date, subject to the director’s continued service as a director, and will become exercisable in full upon a change in control. The number of shares subject to this annual option grant was 3,333 in 2024 (after giving effect to the 1-for-12 reverse split of our common stock effected in July 2024). The number of shares subject to the annual award (which aligned the equity compensation component of our non-employee director compensation policy with the 50 th percentile of our peer group from a percent of company approach) was approved by our Board, upon the recommendation of the Compensation Committee, which was based on, and consistent with, Aon's recommendation, which recommendation was based on an assessment of the market data of our 2024 peer group.

Initial Award . Each director newly elected to our Board receives an option to purchase shares of our common stock, which vests as to one-third of the shares on each anniversary of the grant date until the third anniversary of the grant date, subject to the director’s continued service as a director, and will become exercisable in full upon a change in control. The number of shares subject to this initial award was 5,000 in 2024 (after giving effect to the 1-for-12 reverse split of our common stock effected in July 2024). No such awards were granted in